Research & Development
-
Getty Images
3 KRAS drugs to watch as the field expands
Revolution’s pancreatic cancer approval marked a milestone in RAS-targeted treatment. Now, new treatments from Revolution, Astellas and Genentech could be the next to make a mark on the space.
By Kelly Bilodeau • Sept. 15, 2026 -
Permission granted by Cocrystal Pharma
Q&A // First 90 DaysCocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for the vexing stomach bug.
By Alexandra Pecci • Sept. 15, 2026 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Westy72 via Getty Images
PDUFA reauthorization offers a chance at clinical trial reforms. Will the US take it?
The reauthorization could give Congress the opportunity to help streamline clinical trials and accelerate drug research.
By Kelly Bilodeau • Sept. 14, 2026 -
howtogoto via Getty Images
Cancer still dominates pharma R&D. Obesity is gaining ground.
Oncology still accounts for nearly two out of five pipeline drugs, while obesity entered the top 10 indications and one-third of drugs target at least one rare disease.
By Alexandra Pecci • Sept. 11, 2026 -
Getty Images
mRNA cancer vaccines’ biggest barriers to market
Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.
By Alexandra Pecci • Sept. 10, 2026 -
Getty Images
5 questions that could determine Alzheimer’s next chapter
“The Alzheimer’s space has really got a fire under it,” says one analyst. But can the momentum deliver better drugs?
By Kelly Bilodeau • Sept. 9, 2026 -
Getty Images
Merck pairs ADCs with Keytruda in women’s cancer push
The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff.
By Kelly Bilodeau • Sept. 9, 2026 -
Scott Olson/Staff via Getty Images
Prediction markets are putting a price on pharma’s secrets. Here’s what companies need to know.
As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information.
By Sy Mukherjee • Sept. 8, 2026 -
Justin Sullivan via Getty Images
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
By PharmaVoice Staff • Sept. 4, 2026 -
Joe Raedle via Getty Images
As measles outbreaks soar, where does drug R&D stand?
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up against a tense market environment.
By Alexandra Pecci • Sept. 4, 2026 -
Getty Images
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
By Jonathan Gardner • Sept. 3, 2026 -
Andrew Harnik via Getty Images
China’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
By Kelly Bilodeau • Sept. 3, 2026 -
Getty Images
The hidden scale-out problem behind CAR-T’s growth
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether.
By Sy Mukherjee • Sept. 1, 2026 -
Getty Images
Social anxiety drugs have been floundering in the clinic. Could Eli Lilly help tip the scales?
After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year.
By Alexandra Pecci • Aug. 31, 2026 -
Sponsored by ICON
Advances in risk assessment shift the calculus of early intervention trials for MASLD
How risk prediction is making early intervention trials in MASLD more feasible.
By Jolanta M. Wichary, MD, Vice President, Therapeutic Area Lead, Gastroenterology and Hepatology and Jack Martin, MD, FACC, Senior Director, Cardiovascular Therapeutics, Drug Development Solutions, ICON • Aug. 31, 2026 -
Alamy
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
By Delilah Alvarado • Aug. 28, 2026 -
Permission granted by Argenx
Q&A // First 90 DaysA single drug made Argenx one of the most valuable biotechs in Europe. Its new CEO is ready for the next act.
Under its new chief, Karen Massey, Argenx is positioning its blockbuster Vyvgart to become the Keytruda of the autoimmune disease space.
By Meagan Parrish • Aug. 28, 2026 -
Permission granted by GSK
Pharma’s new CEOs to watch
New leaders at GSK, Novo Nordisk and Sanofi are taking the reins at pivotal moments for three of pharma’s largest companies.
By Kelly Bilodeau • Aug. 27, 2026 -
Getty Images
3 takeover targets in immunology
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&AIs AI finally proving its worth in drug R&D?
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas?
By Kelly Bilodeau • Aug. 26, 2026 -
Getty Images
Q&ALegend’s interim CEO sees a shorter path to the next era of CAR-T
Alan Bash explains how Carvykti informed the company’s strategy and what its in vivo platform still needs to prove.
By Sy Mukherjee • Aug. 25, 2026 -
Claudio Ventrella via Getty Images
3 potential blockbusters beyond obesity to watch
Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial upside.
By Alexandra Pecci • Aug. 24, 2026 -
Permission granted by Tyra Biosciences
Tyra’s one-drug, three-indication bet nears its first phase 2 test
What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline.
By Alexandra Pecci • Aug. 21, 2026 -
Getty Images
Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod
A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower doses of its obesity pill.
By PharmaVoice Staff • Aug. 21, 2026 -
Getty Images
OpinionThe scientific research pharma leaders keep sharing — and why
Six industry leaders share the scientific papers they keep circulating, spanning transplants, MASH, cancer, real-world evidence and trial design.
By Kelly Bilodeau • Aug. 20, 2026
